Evidence map›Paper›PMID 39644505›Full record

ArticleESC heart failure2025

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation.

Francesco Curcio, Cristiano Amarelli, Rosaria Chiappetti, Irene Mattucci, Veronica Flocco, Mahmoud Issa Rammal, Ciro Abete, Francesca Mazzella, Ciro Maiello, Pasquale Abete and 1 more

Abstract read
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Francesco CurcioDepartment of Translational Medical Sciences, University of Naples 'Federico II', Naples, Italy.
Cristiano AmarelliDepartment of Cardiac Surgery and Transplants, Monaldi Hospital, Azienda dei Colli, Naples, Italy.
Rosaria ChiappettiDepartment of Translational Medical Sciences, University of Naples 'Federico II', Naples, Italy.
Irene MattucciDepartment of Cardiac Surgery and Transplants, Monaldi Hospital, Azienda dei Colli, Naples, Italy.
Veronica FloccoDepartment of Translational Medical Sciences, University of Naples 'Federico II', Naples, Italy.
Mahmoud Issa RammalDepartment of Translational Medical Sciences, University of Naples 'Federico II', Naples, Italy.
Ciro AbeteDepartment of Translational Medical Sciences, University of Naples 'Federico II', Naples, Italy.
Francesca MazzellaDepartment of Translational Medical Sciences, University of Naples 'Federico II', Naples, Italy.
Ciro MaielloDepartment of Cardiac Surgery and Transplants, Monaldi Hospital, Azienda dei Colli, Naples, Italy.
Pasquale AbeteDepartment of Translational Medical Sciences, University of Naples 'Federico II', Naples, Italy.
Francesco CacciatoreDepartment of Translational Medical Sciences, University of Naples 'Federico II', Naples, Italy.

Funding

European Union - NextGenerationEU - AGE-It Spoke 3PRIN 2020
6 · The paper itself

Abstract

aimsAdvanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end-stage liver disease (MELD) score and its variations in predicting adverse outcomes [death, urgent heart transplant, and left ventricular assist device (LVAD) implant] among patients with AHF to assess the clinical associations of the MELD score in this population and to compare the efficacy of this tool with other prognostic scores in AHF. METHODS AND

resultsIn this longitudinal prospective study, 162 patients with advanced heart failure (AHF) were enrolled; all patients included in the study were receiving the maximum tolerated medical therapy according to guidelines. The MELD score was measured at baseline and every 6 months during follow-up. All patients underwent echocardiographic assessment and cardiopulmonary testing, which included the evaluation of maximal oxygen uptake (VO2max) and the minute ventilation/carbon dioxide production (VE/VCO2) slope. The mean age of the study group was 57.7 ± 11.6 years. There were 26 deaths, 5 urgent transplants, and 1 LVAD implantation during a follow-up period of 31.4 ± 15.6 months. The mean New York Heart Association (NYHA) class was 2.8 ± 0.5, ejection fraction (EF) was 26.3 ± 6.5%, the mean VO2max was 11.7 ± 3.5 mL/kg/min. Multiple regression analysis revealed a positive correlation between the MELD score and NT-proBNP (β = 0.215; P = 0.041) and furosemide dosage (β = 0.187; P = 0.040). Conversely, a negative correlation was observed between the MELD score and TAPSE (β = -0.204; P = 0.047). Multivariate Cox regression on combined outcome shows a HR of 1.094 (95% CI 1.003-1.196) for unit increase in MELD considered as a continuous variable. The predictive role is independent by the effect of covariates considered in the analysis such as age, sex, NYHA class, EF, TAPSE, PASP, VO2max, NT-proBNP, MELD score worsening, and NT-proBNP increase. Changes in MELD score percentage, considered as a dichotomous variable (≤100% and >100%), were found to be predictors of mortality, urgent heart transplant and LVAD implant. Receiver operating characteristic (ROC) curves showed an area under the curve (AUC) of 0.887 for MELD score and composite outcome of death, urgent transplant, and need for LVAD. The predictive performance of MELD was even superior compared with MELD-Na, MELD-XI, MAGGIC risk score, and MECKI.

conclusionsThe MELD score and its longitudinal changes are effective predictors of adverse outcomes in AHF.

Indexed as

End Stage Liver DiseaseHeart FailureQuality of LifeAgedEchocardiographyFemaleFollow-Up StudiesHeart-Assist DevicesHeart TransplantationHumansLongitudinal StudiesMaleMiddle AgedPrognosisProspective StudiesSeverity of Illness IndexAdvanced heart failureHeart transplant listingMELD scoreMortality

Identifiers

PMID39644505
PMCPMC11911564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.